Drugs / Standard-of-Care
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT05316701 Comparator | Jun 2022 → Jul 2024 overdue | acute lymphoblastic leukemia, acute undifferentiated leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome | Orca Biosystems, Inc. | Active not recruiting | Met primary |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Standard-of-Care | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05316701 ↗ |
| Modality | Cell therapy | “an unmanipulated allograft derived from the peripheral blood of a matched donor” NCT05316701 ↗ |